Fusion Acquisition Corp. Files for $250M IPO
by Kristi Marvin on 2020-06-09 at 1:17pm

Fusion Acquisition Corp. (FUSE.U), filed for a $250 million IPO last night, and will be focused on companies with an enterprise value of approximately $750 million to $3 billion and with a particular emphasis on companies in the FinTech sector.

The Fusion team will be led by Jim Ross, as non-Executive Chairman, and John James, as CEO.  For those unfamiliar with Mr. Ross, he is currently a senior advisor to State Street, the financial services company, but he is best known for being the Chairman of the global SPDR exchange-traded fund (“SPDR ETF”).  He is an ETF pioneer having helped bring the first Gold ETF to market (GLD), as well as SPY, which are probably the most recognizable ETFs.  However, as his bio in the prospectus states, “Mr. Ross was also instrumental in creating, developing, and bringing to market many of the world’s first ETFs“.

As for Mr. James, Fusion’s CEO, he most recently founded BetaSmartz, a global financial technology business serving financial services organizations, in 2015, and has served as its chairman and chief executive officer since November 2015. Rounding out the team are Jeffrey Gary, who will be Fusion’s CFO, and the Directors, Kelly Driscoll and Ben Buettell.  All of whom have significant financial services experience. Mr. Gary – portfolio manager at Avenue Capital and Blackrock, Ms. Driscoll – State Street; Mr. Buettell – Houlihan Lokey. So clearly, this team has financial services experience.

Looking at this SPAC’s structure, it’s a fairly standard structure we used to see quite frequently last year.  That is, it’s a $250 million, 1/2 warrant, 18 months life SPAC, with a $7.0 million at-risk purchase of warrants at $1.00.  No forward purchases, or indications of interest, just a straight-up SPAC.  Plus, they have Cantor underwriting the deal (with Odeon Capital as co-manager) and Cantor tends to favor simpler structures without a lot of bells and whistles.

All told, this SPAC should price pretty easily.  They have an experienced underwriter, and the terms feel like a good match for this first time team. Look for Fusion to price the week of June 22nd.

Summary of terms below:

Fusion-Acquisition-Corp. summary of terms

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved